The accelerating speed of change within the pharmaceutical launch environment raises considerable challenges for launch excellence, as companies grapple with a complex and ever-changing wor
As figures show the UK continues to lag behind other developed countries in cancer survival, a new project aims to create a national database with ambitious goals to challenge the variation
New rare disease treatments face a complex market access landscape that presents fundamental challenges for pharmaceutical companies seeking to achieve launch excellence.
Overview
Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.